# US 2016/0252530 A1 · Agent for preventing or treating spinocerebellar ataxia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252530 A1
- Document ID: US20160252530A1
- Status: Published application
- Kind: A1
- Application number: 15/028,571
- Filed: 2014-10-10
- Published: 2016-09-01
- Earliest claimed: 2013-10-11
- Assignees: National University Corporation Tokyo Medical and Dental University
- Applicants: National University Corporation Tokyo Medical and Dental University
- Inventors: Hitoshi OKAZAWA
- Web page: https://patentgrep.com/patent/US20160252530A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 31/465: Nicotine; Derivatives thereof
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 31/4748: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
- A61K 31/497: containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 49/0058: {Antibodies}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/485: {involving kinase}
- C12Q 1/6897: involving reporter genes operably linked to promoters
- G01N 33/5058: {Neurological cells}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- G01N 2800/28: Neurological disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

To provide a compound which enables treatment or prevention of spinocerebellar ataxia, analyses were carried out based on a screening using a spinocerebellar ataxia type 1 (SCA1) fly model and on the like. As a result, the following proteins ameliorating the pathology of spinocerebellar ataxia were identified: RPA1, PNKP, XRCC3, XRCC4, CCNH, POLE, POLH, and PERI. On the other hand, the following proteins aggravating the pathology were identified: CHK1, LIG3, FEN1, LIG1, ERCC5, XAB2, ERCC2, DMC1, RECQL5, MUS81, EME1, SPO11, and BLM. In addition, it has been revealed that ATXN1, which is a cause of SCA1, binds to RPA1, BRCA1, and BRCA2, and suppresses the activities of these proteins, so that the above-described pathology is caused.

## Claims

### Claim 1

An agent for preventing or treating spinocerebellar ataxia, comprising, as an active ingredient, at least one of the following (a) to (d):
(a) at least one protein selected from the group consisting of RPA1, BRCA1, BRCA2, PNKP, XRCC3, XRCC4, CCNH, POLE, POLH, and PER1 or a nucleic acid encoding the protein;
(b) a compound which enhances expression or activity of at least one protein selected from the group consisting of RPA1, BRCA1, BRCA2, PNKP, XRCC3, XRCC4, CCNH, POLE, POLH, and PER1;
(c) a compound which inhibits binding between ATXN1 and at least one protein selected from the group consisting of RPA1, BRCA1, and BRCA2; and
(d) a compound which suppresses expression or activity of at least one protein selected from the group consisting of CHK1, LIG3, FEN1, LIG1, ERCC5, XAB2, ERCC2, DMC1, RECQL5, MUS81, EME1, SPO11, and BLM.

### Claim 2 (depends on 1)

The agent according to claim 1, wherein
a compound which suppresses activity of CHK1 protein is contained as the active ingredient, and
the compound is at least one compound selected from the group consisting of
4-[((3S)-1-azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benz imidazol-2-yl)-6-chloroquinolin-2(1H)-one,
(S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)pheny 1)-3-(5-methylpyrazin-2-yl)urea,
6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(3R)-3-piperidinylpyrazolo[1,5-a]pyrimidine-7-amine,
(R)-α-amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-cyclohexaneacetamide,
1-(2-((S)-piperidin-3-ylcarbamoyl)-5-(3-fluorophenyl)thiophen-3-yl)urea, XL844, 7-hydroxystaurosporine,
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)nicotinamide,
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)isobutylamide,
(R)—N-(5-bromo-4-(3-(methylamino)piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide,
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)-5-methylnicotinamide,
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)cyclopropanecarboxamide,
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)-3-methyl-butanamide, and
(R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2, 3-b]pyridin-3-yl)-2-cyclopropylacetamide.

### Claim 3

A screening method for a candidate compound for preventing or treating spinocerebellar ataxia, the method comprising the following steps (a) to (c):
(a) bringing ATXN1 and at least one protein selected from the group consisting of RPA1, BRCA1, and BRCA2 into contact with each other in the presence of an analyte compound,
(b) detecting binding between the ATXN1 and the at least one protein selected from the group consisting of RPA1, BRCA1, and BRCA2; and
(c) selecting the compound, if the compound inhibits the binding.

### Claim 4

A screening method for a candidate compound for preventing or treating spinocerebellar ataxia, the method comprising the following steps (a) and (b):
(a) applying an analyte compound to a system in which expression or activity of at least one protein selected from the group consisting of RPA1, BRCA1, BRCA2, PNKP, XRCC3, XRCC4, CCNH, POLE, POLH, and PER1 is detectable; and
(b) selecting the compound, if the compound enhances the expression or the activity of the protein.

### Claim 5

A screening method for a candidate compound for preventing or treating spinocerebellar ataxia, the method comprising the following steps (a) and (b):
(a) applying an analyte compound to a system in which a function of at least one protein selected from the group consisting of CHK1, LIG3, FEN1, LIG1, ERCC5, XAB2, ERCC2, DMC1, RECQL5, MUS81, EME1, SPO11, and BLM is detectable; and
(b) selecting the compound, if the compound suppresses expression or activity of the protein.
